

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Please amend the claims as follows, wherein strikeout [00] indicates deleted terminology and underlining [00] indicates added terminology.

1. (Currently amended) An isolated antibody which is not a native IgM or IgA antibody, the isolated antibody comprising an Fc region and three or more antigen binding sites amino-terminal to the Fc region comprising at least one polypeptide chain with the formula:
(a) VH-CH1-flexible linker-VH-CH1-Fc region chain, wherein the flexible linker comprises the peptide gly-ser-gly-ser (SEQ ID NO:10).
2. (Original) The antibody of claim 1 comprising four antigen binding sites.
- 3.-5. (Canceled)
6. (Currently amended) The antibody of claim 1~~[5]~~ comprising two or more of the polypeptide chains, ~~each comprising~~ VD1-(X1)_n-VD2-(X2)_n-Fc.
7. (Canceled)
8. (Original) The antibody of claim 1 comprising at least two light chain variable domain polypeptides.
9. (Original) The antibody of claim 8 wherein the light chain variable domain polypeptides further comprise a CL domain.
- 10.-11. (Canceled)
12. (Original) The antibody of claim 1 which is internalized faster than a bivalent antibody by a cell expressing an antigen to which the antibodies bind.
13. (Original) The antibody of claim 1 which is an agonist antibody.
14. (Original) The antibody of claim 1 which induces apoptosis.

15. (Original) The antibody of claim 1 wherein the three or more antigen binding sites all bind the same antigen.
- 16.-20. (Canceled)
21. (Previously presented) The antibody of claim 1 which binds a DR5 receptor.
22. - 24. (Cancelled)
25. (Original) The antibody of claim 21 which is an agonist antibody.
26. (Original) The antibody of claim 21 which induces apoptosis.
- 27.-68. (Canceled)
69. (Currently amended) The polypeptide chain of claim 1~~[66]~~ wherein the antigen is a DR5 receptor.
- 70-73. (Canceled)
74. (Currently amended) The polypeptide chain of claim 1~~[68]~~ comprising the formula:
- (a) VH-CH1-flexible linker-VH-CH1-flexible linker-VH-CH1; or
 - (b) VH-CH1-flexible linker-VH-CH1-flexible linker-VH-CH1-flexible linker-VH-CH1;₂
 - ~~(c) (VH-CH1)_n, wherein n is three or four.~~
- 75.-79. (Canceled)
80. (Currently amended) An immunoconjugate comprising the antibody of claim 1~~[75]~~ conjugated with a cytotoxic agent.
- 81-93. (Cancelled)